Visual hallucinosis in patients with Parkinson’s disease

Aim. To determine the effect of visual impairment on the formation of visual hallucinosis.

Materials and methods. We studied 87 patients with Parkinson’s disease (PD). The average age of the patients was 65.16 ± 8.22 years. The patients underwent a comprehensive neurological and ophthalmological examination, including optical coherence tomography of the retina.

Results. The presence of visual hallucinosis was reported by 50.6 % of patients with PD. Extracampine hallucinations (ECH) are the most common. ECH was detected at all stages of PD and in patients with different forms of the disease and patients with ECH have no cognitive impairment. In patients with ECH, there was no decrease in visual acuity, impaired color perception, contrast sensitivity, as well as ophthalmic diseases such as cataracts, glaucoma, etc. An important difference between patients with ECH and patients without ECH was a statistically significant thinning of the retinal layers. Complaints about the presence of illusions were detected in 18.4 % of patients with PD. According to the results of our study, patients with illusions were characterized by a marked decrease in visual acuity, impaired color perception and contrast sensitivity, and, apparently, the presence of illusions in patients with PD can be explained by impaired visual perception and amblyopia. According to the results of neuropsychological testing, patients with illusions have impaired visual-spatial functions. Visual hallucinationsis appeared in the late-stages of PD, patients over 65 years of age with mild cognitive impairment.

Сonclusion. As a result of our study, it was revealed that the development of visual hallucinosis in patients with PD is associated not only with central (cortical) mechanisms, but the peripheral part of the visual analyzer is also of considerable importance, primarily retinal damage and loss of visual afferentation.

1. Pagonabarraga J., Martinez-Horta S., de Bobadilla R.F. et al. Minor hallucinations occur in drug-naïve Parkinson`s disease patients, even from the premotor phase. Mov Disord 2016;31(1):45–52. DOI: 10.1002/mds.26432

2. Lenka A., Pagonabarraga J., Pal P.K. et al. Minor hallucinations in Parkinson`s disease: a subtle symptom with major clinical implications. Neurology 2019;93(6):259–66. DOI: 10.1212/WNL.0000000000007913

3. Yokoi K., Nishio Y., Uchiyama M. et al. Hallucinators find meaning in noises: pareidolic illusions in dementia with Lewy bodies. Neuropsychologia 2014;56:245–54. DOI: 10.1016/j.neuropsychologia.2014.01.017

4. Kurumada K., Sugiyama A., Hirano S. et al. Pareidolia in Parkinson’s Disease and Multiple System Atrophy. Parkinsons Dis 2021;2021:2704755. DOI: 10.1155/2021/2704755

5. Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015;30(12):1591–601. DOI: 10.1002/mds.26424

6. Levin O.S., Fedorova N.V. Parkinson disease. Moscow: MEDpressinform, 2015. (In Russ.).

7. Borm C.D.J.M., Visser F., Werkmann M. et al. Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaire. Neurology 2020;94(14):e1539–47. DOI: 10.1212/WNL.0000000000009214

8. Nasreddine Z.S. Phillips N.A., Bédirian V. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53(4):695–9. DOI: 10.1111/j.1532–5415.2005.53221.x

9. Gutorova D.A., Vasenina E.E., Levin O.S. Screening of cognitive impairment in the old and old-old population with the 3-CT scale. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova = C.C. Korsakov Journal of Neurology and Psychiatry 2016;116(6–2): 35–40. (In Russ.). DOI: 10.17116/jnevro20161166235-40

10. Salazar J.J., Ramirez A.I., De Hoz R. et al. Anatomy of the Human Optic Nerve: Structure and Function. Optic Nerve. IntechOpen 2019. DOI: 10.5772/intechopen.79827

11. Qian Y., Zou J., Zhang Z. et al. Robust functional mapping of layerselective responses in human lateral geniculate nucleus with highresolution 7T fMRI. Proc Biol Sci 2020;B287(1925):20200245. DOI: 10.1098/rspb.2020.0245

12. Huchzermeyer C., Horn F., Lämmer R. et al. Summation of Temporal L-Cone- and M-Cone-Contrast in the Magnoand Parvocellular Retino-Geniculate Systems in Glaucoma. Invest Ophthalmol Vis Sci 2021;62(6):17. DOI: 10.1167/iovs.62.6.17

13. Edwards M., Goodhew S.C., Badcock D.R. Using perceptual tasks to selectively measure magnocellular and parvocellular performance: Rationale and a user’s guide. Psychon Bull Rev 2021;28:1029–50. DOI: 10.3758/s13423-020-01874-w

14. Bear M.F., Paradiso M.A., Connors B.V. Neuroscience. Brain research: in 3 vol. Vol. 1. Trans. from English. Kiev: Dialectics, 2020. (In Russ.).

15. Wurtz R.H., Kandel E.R. Central visual pathways. In: Principles of neural science/ E.R. Kandel, J.H. Schwartz, T.M. Jessel (Eds.). New York: McGraw-Hill, 2000. P. 523–47.

16. Bejr-Kasem H., Pagonabarraga J., Martinez-Horta S. et al. Disruption of default mode network and its intrinsic functional connectivity underlines minor hallucinations in Parkinson`s disease. Mov Disord 2019;34(1):78–86. DOI: 10.1002/mds.27557

17. Jones L., Ditzel-Finn L., Enoch J., Moosajee M. An overview of psychological and social factors in Charles Bonnet syndrome. Ther Adv Ophthalmol 2021;13:25158414211034715. DOI: 10.1177/25158414211034715

18. Lee W.W., Yoon E.J., Lee J.Y. et al. Visual hallucinations and pattern of brain degeneration in Parkinson`s disease. Neurodegener Dis 2017;17(2–3):62–72. DOI: 10.1159/000448517